ERYGEL Drug Patent Profile
✉ Email this page to a colleague
When do Erygel patents expire, and when can generic versions of Erygel launch?
Erygel is a drug marketed by Mylan and is included in one NDA.
The generic ingredient in ERYGEL is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erygel
A generic version of ERYGEL was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYGEL?
- What are the global sales for ERYGEL?
- What is Average Wholesale Price for ERYGEL?
Summary for ERYGEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 5,330 |
| Drug Prices: | Drug price information for ERYGEL |
| What excipients (inactive ingredients) are in ERYGEL? | ERYGEL excipients list |
| DailyMed Link: | ERYGEL at DailyMed |
Pharmacology for ERYGEL
| Drug Class | Macrolide Antimicrobial Macrolide |
| Physiological Effect | Decreased Sebaceous Gland Activity |
US Patents and Regulatory Information for ERYGEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | ERYGEL | erythromycin | GEL;TOPICAL | 050617-001 | Oct 21, 1987 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
